These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 33741916)
1. A comprehensive influenza reporter virus panel for high-throughput deep profiling of neutralizing antibodies. Creanga A; Gillespie RA; Fisher BE; Andrews SF; Lederhofer J; Yap C; Hatch L; Stephens T; Tsybovsky Y; Crank MC; Ledgerwood JE; McDermott AB; Mascola JR; Graham BS; Kanekiyo M Nat Commun; 2021 Mar; 12(1):1722. PubMed ID: 33741916 [TBL] [Abstract][Full Text] [Related]
2. Mapping of a Novel H3-Specific Broadly Neutralizing Monoclonal Antibody Targeting the Hemagglutinin Globular Head Isolated from an Elite Influenza Virus-Immunized Donor Exhibiting Serological Breadth. Qiu Y; Stegalkina S; Zhang J; Boudanova E; Park A; Zhou Y; Prabakaran P; Pougatcheva S; Ustyugova IV; Vogel TU; Mundle ST; Oomen R; Delagrave S; Ross TM; Kleanthous H; Qiu H J Virol; 2020 Feb; 94(6):. PubMed ID: 31826999 [TBL] [Abstract][Full Text] [Related]
3. Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses. Allen JD; Jang H; DiNapoli J; Kleanthous H; Ross TM J Virol; 2019 Feb; 93(3):. PubMed ID: 30429350 [TBL] [Abstract][Full Text] [Related]
4. Potential Role of Nonneutralizing IgA Antibodies in Cross-Protective Immunity against Influenza A Viruses of Multiple Hemagglutinin Subtypes. Okuya K; Yoshida R; Manzoor R; Saito S; Suzuki T; Sasaki M; Saito T; Kida Y; Mori-Kajihara A; Kondoh T; Sato M; Kajihara M; Miyamoto H; Ichii O; Higashi H; Takada A J Virol; 2020 Jun; 94(12):. PubMed ID: 32269119 [TBL] [Abstract][Full Text] [Related]
5. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies. Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855 [TBL] [Abstract][Full Text] [Related]
11. A highly conserved neutralizing epitope on group 2 influenza A viruses. Ekiert DC; Friesen RH; Bhabha G; Kwaks T; Jongeneelen M; Yu W; Ophorst C; Cox F; Korse HJ; Brandenburg B; Vogels R; Brakenhoff JP; Kompier R; Koldijk MH; Cornelissen LA; Poon LL; Peiris M; Koudstaal W; Wilson IA; Goudsmit J Science; 2011 Aug; 333(6044):843-50. PubMed ID: 21737702 [TBL] [Abstract][Full Text] [Related]
12. Different genetic barriers for resistance to HA stem antibodies in influenza H3 and H1 viruses. Wu NC; Thompson AJ; Lee JM; Su W; Arlian BM; Xie J; Lerner RA; Yen HL; Bloom JD; Wilson IA Science; 2020 Jun; 368(6497):1335-1340. PubMed ID: 32554590 [TBL] [Abstract][Full Text] [Related]
13. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. Margine I; Krammer F; Hai R; Heaton NS; Tan GS; Andrews SA; Runstadler JA; Wilson PC; Albrecht RA; GarcĂa-Sastre A; Palese P J Virol; 2013 Oct; 87(19):10435-46. PubMed ID: 23903831 [TBL] [Abstract][Full Text] [Related]
14. Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants. Wong TM; Allen JD; Bebin-Blackwell AG; Carter DM; Alefantis T; DiNapoli J; Kleanthous H; Ross TM J Virol; 2017 Dec; 91(24):. PubMed ID: 28978710 [TBL] [Abstract][Full Text] [Related]
16. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. Wang TT; Tan GS; Hai R; Pica N; Petersen E; Moran TM; Palese P PLoS Pathog; 2010 Feb; 6(2):e1000796. PubMed ID: 20195520 [TBL] [Abstract][Full Text] [Related]
17. Implications of broadly neutralizing antibodies in the development of a universal influenza vaccine. Cho A; Wrammert J Curr Opin Virol; 2016 Apr; 17():110-115. PubMed ID: 27031684 [TBL] [Abstract][Full Text] [Related]